ArticleAlzheimer's research & therapy2016
A digital enzyme-linked immunosorbent assay for ultrasensitive measurement of amyloid-β 1-42 peptide in human plasma with utility for studies of Alzheimer's disease therapeutics.
Article in Alzheimer's research & therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 83 citations in OpenAlex.
- Composition and activity of the proteasome in human iPSC-derived neuronal model of early-stage sporadic Alzheimer's disease.bioRxiv : the preprint server for biology · 2026Article
- ADNI Biomarker Core: A review of progress since 2004 and future challenges.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Review
- Label-free detection of Aβ-42: a liquid crystal droplet approach for Alzheimer's disease diagnosis.RSC advances · 2024Article
- Biomarker Assessment in Parkinson's Disease Dementia and Dementia with Lewy Bodies by the Immunomagnetic Reduction Assay and Clinical Measures.Journal of Alzheimer's disease reports · 2024Article
- Review
- Neuroimaging based biotypes for precision diagnosis and prognosis in cancer-related cognitive impairment.Frontiers in medicine · 2023Review
- Visinin-like protein 1 levels in blood and CSF as emerging markers for Alzheimer's and other neurodegenerative diseases.Alzheimer's research & therapy · 2022Article
- Recent advances in pre-clinical diagnosis of Alzheimer's disease.Metabolic brain disease · 2022Review
- Clinically oriented Alzheimer's biosensors: expanding the horizons towards point-of-care diagnostics and beyond.RSC advances · 2021Review
- A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis.Molecular neurodegeneration · 2021Article
- The Diagnostic Potential of Amyloidogenic Proteins.International journal of molecular sciences · 2021Review
- A β-AmyloidJournal of biomedical physics & engineering · 2021Article
- Bioinspired Synthesis of ZnO@polydopamine/Au for Label-Free Photoelectrochemical Immunoassay of Amyloid-β Protein.Frontiers in bioengineering and biotechnology · 2021Article
- A Novel Bead-Based Immunoassay for the Measurement of Heat Shock Proteins 27 and 70.Pathogens (Basel, Switzerland) · 2020Article
- Label-Free Optical Resonator-Based Biosensors.Sensors (Basel, Switzerland) · 2020Review
- Au nano-urchins enabled localized surface plasmon resonance sensing of beta amyloid fibrillation.Nanoscale advances · 2020Article
- On-Chip Detection of the Biomarkers for Neurodegenerative Diseases: Technologies and Prospects.Micromachines · 2020Review
- Au/NiFeNanoscale advances · 2020Article
- A Sensitive and Cost-Effective Chemiluminescence ELISA for Measurement of Amyloid-β 1-42 Peptide in Human Plasma.Journal of Alzheimer's disease : JAD · 2020Article
- Advance in Plasma AD Core Biomarker Development: Current Findings from Immunomagnetic Reduction-Based SQUID Technology.Neurology and therapy · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAmyloid-β 1-42 peptide (Aβ
methodsA sensitive digital ELISA for measurement of Aβ
resultsThe prototype assay measured Aβ
conclusionsThis digital ELISA has potential utility in clinical applications for quantification of Aβ
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.